Publications in collaboration with researchers from Dana–Farber Cancer Institute (26)

2023

  1. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

  2. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

    British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294

2022

  1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

    Blood, Vol. 140, Núm. 11, pp. 1200-1228

2021

  1. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression

    Blood Cancer Journal, Vol. 11, Núm. 7

  2. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 727-736

2020

  1. A reference map of the human binary protein interactome

    Nature, Vol. 580, Núm. 7803, pp. 402-408

  2. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

    Leukemia, Vol. 34, Núm. 6, pp. 1599-1612

  3. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications

    International Journal of Cancer, Vol. 147, Núm. 10, pp. 2780-2792

2019

  1. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence

    Journal of Experimental Medicine, Vol. 216, Núm. 5, pp. 1108-1119

  2. DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains

    Experimental Hematology, Vol. 72, pp. 9-13

  3. Maximizing binary interactome mapping with a minimal number of assays

    Nature Communications, Vol. 10, Núm. 1

  4. Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma

    Journal of Clinical Oncology

  5. Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma ¨

    Journal of Clinical Oncology

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia

    American Journal of Hematology, Vol. 91, Núm. 10, pp. 978-983

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  4. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346

  5. Multidisciplinary approach of unresectable head and neck cancer

    Head and Neck Cancer: Multimodality Management, Second Edition (Springer International Publishing), pp. 617-624

2015

  1. Identification of six new susceptibility loci for invasive epithelial ovarian cancer

    Nature Genetics, Vol. 47, Núm. 2, pp. 164-171